Ticker LaunchIPO · MAIA
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (MAIA) priced its initial public offering on Jul 29, 2022 at $5.00 per share, within its $5.00–$7.00 range, raising $10M, and listed on NYSE American. At the IPO price its market capitalization was about $53.2M. ThinkEquity was lead-left underwriter. Loeb & Loeb advised the company and Venable advised the underwriters.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Its lead drug candidate, THIO, is in a Phase 2 trial (THIO-101) in advanced non-small cell lung cancer, where it is given before the checkpoint inhibitor Libtayo.
- Status
- IPO
- Ticker
- MAIA
- Exchange
- NYSE American
- Priced
- Jul 29, 2022
- IPO price
- $5.00
- Price range
- $5.00–$7.00
- Raised
- $10M
- Market cap at IPO price
- $53.2M
- First filed
- Apr 11, 2022
- Underwriters
- ThinkEquity
- Company counsel
- Loeb & Loeb
- Underwriters' counsel
- Venable
- Sector
- Biotech & pharma
- Country / state
- IL
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 11, 2022
- Latest amendment Jul 21, 2022
- Final prospectus (424B4) Jul 29, 2022
- All filings on EDGAR CIK 1878313
Other Biotech & pharma IPOs in 2022
- Third Harmonic Bio, Inc.THRD · Sep 15, 2022 · $185.3M
- bioAffinity Technologies, Inc.BIAF · Sep 2, 2022 · $7.9M
- Shuttle Pharmaceuticals Holdings, Inc.SHPH · Aug 31, 2022 · $10M
- Kuvatris Therapeutics, Inc.PXMD · Aug 29, 2022
- Virax Biolabs Group LtdVRAX · Jul 21, 2022
- OKYO Pharma LtdOKYO · May 18, 2022 · $2.5M